Tugba Yildiran Ozmen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tugba Yildiran Ozmen has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Gordon Brent Mills
Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
54 shared publications - Furkan Ozmen
Knight Cancer Institute 4 Division of Oncological Sciences , Portland, Oregon
51 shared publications - Lisa M. Coussens
Oregon Health & Science University 2 Department of Cell, Developmental and Cancer Biology Portland, Oregon
34 shared publications - Shamilene Sivagnanam
Oregon Health & Science University 2 Department of Cell, Developmental and Cancer Biology Portland, Oregon
34 shared publications - Amber Hoffman
Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, Oregon
32 shared publications - Aryn A. Alanizi
Department of Anatomy, University of California, San Francisco, San Francisco, California
32 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF20
IFNγ-Dependent Tumor-Cell MHC-II Is Restrained by MAPK Signaling and Associated with Immunotherapy Responsiveness in Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is characterized by an immunosuppressive tumor microenvironment (TME) and poor prognosis. Although major histocompatibility complex class II (MHC-II) is typically expressed by professional antigen-presenting cells, its regulation and significance in malignant PDAC cells remain unclear. In this study, we integrated single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, bulk transcriptomics, multiplex immunohistochemistry (mIHC), and functional studies in murine PDAC models to investigate tumor-cell MHC-II. Across human PDAC datasets, elevated tumor-cell MHC-II expression was associated with increased CD4+ and CD8+ T-cell infiltration and localization within immune-rich tumor niches. In paired biopsies from patients treated with cobimetinib, malignant cells showed increased expression of MHC-II pathway genes, suggesting therapy-induced activation of this program. In preclinical KPC models, MHC-IIhigh tumors exhibited greater T-cell infiltration, whereas MHC-IIlow tumors derived the greatest benefit from cobimetinib combined with immune checkpoint blockade (ICB). Mechanistically, direct tumor stimulation via in vitro administration of cobimetinib and recombinant interferon (IFN) γ (rIFNγ) resulted in MHC-II induction in vitro by both MHC-IIhigh and MHC-IIlow PDAC cell lines. In vivo, combined MEK inhibition and ICB controlled tumor growth, including in MHC-IIlow tumors. Deletion of the IFNγ receptor abolished MHC-II induction and therapeutic benefit, demonstrating that this response is IFNγ dependent. MEK inhibition enhanced downstream IFNγ signaling, and the combination was required for MHC-II upregulation in vitro, indicating that MAPK activity restrains an IFNγ-responsive MHC-II program. Collectively, these findings identify tumor-cell MHC-II as an IFNγ-dependent, MAPK-restrained program that denotes immunotherapy sensitivity in PDAC.
- 26 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF20
Open AccessIFNγ-Dependent Tumor-Cell MHC-II Is Restrained by MAPK Signaling and Associated with Immunotherapy Responsiveness in Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is characterized by an immunosuppressive tumor microenvironment (TME) and poor prognosis. Although major histocompatibility complex class II (MHC-II) is typically expressed by professional antigen-presenting cells, its regulation and significance in malignant PDAC cells remain unclear. In this study, we integrated single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, bulk transcriptomics, multiplex immunohistochemistry (mIHC), and functional studies in murine PDAC models to investigate tumor-cell MHC-II. Across human PDAC datasets, elevated tumor-cell MHC-II expression was associated with increased CD4+ and CD8+ T-cell infiltration and localization within immune-rich tumor niches. In paired biopsies from patients treated with cobimetinib, malignant cells showed increased expression of MHC-II pathway genes, suggesting therapy-induced activation of this program. In preclinical KPC models, MHC-IIhigh tumors exhibited greater T-cell infiltration, whereas MHC-IIlow tumors derived the greatest benefit from cobimetinib combined with immune checkpoint blockade (ICB). Mechanistically, direct tumor stimulation via in vitro administration of cobimetinib and recombinant interferon (IFN) γ (rIFNγ) resulted in MHC-II induction in vitro by both MHC-IIhigh and MHC-IIlow PDAC cell lines. In vivo, combined MEK inhibition and ICB controlled tumor growth, including in MHC-IIlow tumors. Deletion of the IFNγ receptor abolished MHC-II induction and therapeutic benefit, demonstrating that this response is IFNγ dependent. MEK inhibition enhanced downstream IFNγ signaling, and the combination was required for MHC-II upregulation in vitro, indicating that MAPK activity restrains an IFNγ-responsive MHC-II program. Collectively, these findings identify tumor-cell MHC-II as an IFNγ-dependent, MAPK-restrained program that denotes immunotherapy sensitivity in PDAC.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Data from Comprehensive Multi-Omic Profiling of Desmoplastic Small Round Cell Tumors Identifies Targetable Pathways with Therapeutic Opportunities
Desmoplastic small round cell tumor (DSRCT) is a rare, aggressive, fusion-driven sarcoma with poor outcomes despite intensive chemotherapy. Utilization of targeted therapies in DSRCT remains limited, underscoring the need for deeper characterization of patient tumors. To address this, we performed multi-omic profiling on nine patient-derived tumor biopsies from five patients enrolled in a precision oncology program. We consistently observed elevated mRNA and protein expression of human epidermal growth factor receptor 2, androgen receptor, and DNA damage response (DDR) markers, and characterized these molecular features using an integrated assay suite including bulk and single-cell RNA sequencing, protein profiling, immunohistochemistry, immune analyses, and functional homologous recombination deficiency (HRD) testing. We define a replication stress–associated DNA damage landscape and identify functional HRD in a subset of tumors lacking genomic HRD scar signatures. Single-cell analyses reveal intratumoral and intertumoral heterogeneity, whereas longitudinal sampling uncovers treatment-dependent shifts in expression and activity that may contribute to adaptive resistance. The immune microenvironment is characterized by dysfunctional T-cell states and sparse antigen-presenting cells. Collectively, these analyses delineate recurrent, biologically targetable features and patient-specific vulnerabilities, establishing a foundation for biomarker-guided therapeutic strategies in DSRCT. These findings support the investigation of rational combination approaches informed by sensitive detection methods and functional testing to address resistance in ultra-rare cancers. Implications:Integrative multi-omic profiling combined with functional testing in DSRCTs reveals patient-specific vulnerabilities and biologically targetable receptor and DDR dependencies while defining immune states that may inform therapeutic response and rational combination strategies in this rare, fusion-driven cancer.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Comprehensive Multi-Omic Profiling of Desmoplastic Small Round Cell Tumors Identifies Targetable Pathways with Therapeutic Opportunities
Desmoplastic small round cell tumor (DSRCT) is a rare, aggressive, fusion-driven sarcoma with poor outcomes despite intensive chemotherapy. Utilization of targeted therapies in DSRCT remains limited, underscoring the need for deeper characterization of patient tumors. To address this, we performed multi-omic profiling on nine patient-derived tumor biopsies from five patients enrolled in a precision oncology program. We consistently observed elevated mRNA and protein expression of human epidermal growth factor receptor 2, androgen receptor, and DNA damage response (DDR) markers, and characterized these molecular features using an integrated assay suite including bulk and single-cell RNA sequencing, protein profiling, immunohistochemistry, immune analyses, and functional homologous recombination deficiency (HRD) testing. We define a replication stress–associated DNA damage landscape and identify functional HRD in a subset of tumors lacking genomic HRD scar signatures. Single-cell analyses reveal intratumoral and intertumoral heterogeneity, whereas longitudinal sampling uncovers treatment-dependent shifts in expression and activity that may contribute to adaptive resistance. The immune microenvironment is characterized by dysfunctional T-cell states and sparse antigen-presenting cells. Collectively, these analyses delineate recurrent, biologically targetable features and patient-specific vulnerabilities, establishing a foundation for biomarker-guided therapeutic strategies in DSRCT. These findings support the investigation of rational combination approaches informed by sensitive detection methods and functional testing to address resistance in ultra-rare cancers. Implications:Integrative multi-omic profiling combined with functional testing in DSRCTs reveals patient-specific vulnerabilities and biologically targetable receptor and DDR dependencies while defining immune states that may inform therapeutic response and rational combination strategies in this rare, fusion-driven cancer.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Comprehensive Multi-Omic Profiling of Desmoplastic Small Round Cell Tumors Identifies Targetable Pathways with Therapeutic Opportunities
Figure S1. Comparison of H&Es, HER2 IHC, and AR IHC in Pt4 and Pt5 longitudinal specimens.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Comprehensive Multi-Omic Profiling of Desmoplastic Small Round Cell Tumors Identifies Targetable Pathways with Therapeutic Opportunities
Figure S1. Comparison of H&Es, HER2 IHC, and AR IHC in Pt4 and Pt5 longitudinal specimens.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Comprehensive Multi-Omic Profiling of Desmoplastic Small Round Cell Tumors Identifies Targetable Pathways with Therapeutic Opportunities
Figure S2. HER/EGFR family expression and activity assessment in DSRCT specimens.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Comprehensive Multi-Omic Profiling of Desmoplastic Small Round Cell Tumors Identifies Targetable Pathways with Therapeutic Opportunities
Figure S2. HER/EGFR family expression and activity assessment in DSRCT specimens.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Comprehensive Multi-Omic Profiling of Desmoplastic Small Round Cell Tumors Identifies Targetable Pathways with Therapeutic Opportunities
Figure S4. RPPA protein expression of HER/EGFR family, AR, and DNA damage markers in DSRCT samples compared to a mixed TCGA and SMMART cohort.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Comprehensive Multi-Omic Profiling of Desmoplastic Small Round Cell Tumors Identifies Targetable Pathways with Therapeutic Opportunities
Figure S4. RPPA protein expression of HER/EGFR family, AR, and DNA damage markers in DSRCT samples compared to a mixed TCGA and SMMART cohort.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Comprehensive Multi-Omic Profiling of Desmoplastic Small Round Cell Tumors Identifies Targetable Pathways with Therapeutic Opportunities
Figure S3. mRNA expression of HER/EGFR family, AR, and DNA damage genes in DSRCT specimens, compared to a mixed TCGA and SMMART sarcoma cohort.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Comprehensive Multi-Omic Profiling of Desmoplastic Small Round Cell Tumors Identifies Targetable Pathways with Therapeutic Opportunities
Figure S3. mRNA expression of HER/EGFR family, AR, and DNA damage genes in DSRCT specimens, compared to a mixed TCGA and SMMART sarcoma cohort.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Comprehensive Multi-Omic Profiling of Desmoplastic Small Round Cell Tumors Identifies Targetable Pathways with Therapeutic Opportunities
Figure S5. Fold-change gene expression in DSRCT samples across DNA damage response and repair pathways.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Comprehensive Multi-Omic Profiling of Desmoplastic Small Round Cell Tumors Identifies Targetable Pathways with Therapeutic Opportunities
Figure S5. Fold-change gene expression in DSRCT samples across DNA damage response and repair pathways.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Comprehensive Multi-Omic Profiling of Desmoplastic Small Round Cell Tumors Identifies Targetable Pathways with Therapeutic Opportunities
Figure S7. Immune protein marker expression in DSRCT specimens using DSP compared to a metastatic mixed-subtype breast cancer cohort.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Comprehensive Multi-Omic Profiling of Desmoplastic Small Round Cell Tumors Identifies Targetable Pathways with Therapeutic Opportunities
Figure S7. Immune protein marker expression in DSRCT specimens using DSP compared to a metastatic mixed-subtype breast cancer cohort.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Comprehensive Multi-Omic Profiling of Desmoplastic Small Round Cell Tumors Identifies Targetable Pathways with Therapeutic Opportunities
Figure S6. DNA repair activity in DSRCT specimens inferred by RPPA protein pathway expression and RNA-based GSVA pathway analysis.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Comprehensive Multi-Omic Profiling of Desmoplastic Small Round Cell Tumors Identifies Targetable Pathways with Therapeutic Opportunities
Figure S6. DNA repair activity in DSRCT specimens inferred by RPPA protein pathway expression and RNA-based GSVA pathway analysis.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Comprehensive Multi-Omic Profiling of Desmoplastic Small Round Cell Tumors Identifies Targetable Pathways with Therapeutic Opportunities
Figure S8. Integrated and clustered UMAP visualizations from single cell RNA-seq on Pt3 and Pt5 specimens
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Comprehensive Multi-Omic Profiling of Desmoplastic Small Round Cell Tumors Identifies Targetable Pathways with Therapeutic Opportunities
Figure S8. Integrated and clustered UMAP visualizations from single cell RNA-seq on Pt3 and Pt5 specimens